Clinical trial
A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
NCT00050778 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2002
- Completion date
- January 31, 2010
- Enrollment
- 334 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.